Proteon Therapeutics (NASDAQ: PRTO) is one of 285 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Proteon Therapeutics to related businesses based on the strength of its institutional ownership, analyst recommendations, risk, profitability, dividends, valuation and earnings.

Risk & Volatility

Proteon Therapeutics has a beta of 1.62, indicating that its share price is 62% more volatile than the S&P 500. Comparatively, Proteon Therapeutics’ peers have a beta of 6.01, indicating that their average share price is 501% more volatile than the S&P 500.

Profitability

This table compares Proteon Therapeutics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Proteon Therapeutics N/A -105.58% -77.60%
Proteon Therapeutics Competitors -5,302.67% -356.18% -38.99%

Institutional & Insider Ownership

50.1% of Proteon Therapeutics shares are held by institutional investors. Comparatively, 50.3% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 36.3% of Proteon Therapeutics shares are held by company insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Proteon Therapeutics and its peers top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Proteon Therapeutics $2.95 million -$28.52 million -0.83
Proteon Therapeutics Competitors $284.28 million $34.29 million 134.32

Proteon Therapeutics’ peers have higher revenue and earnings than Proteon Therapeutics. Proteon Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of current ratings for Proteon Therapeutics and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Proteon Therapeutics 0 7 1 0 2.13
Proteon Therapeutics Competitors 848 3199 11594 230 2.71

Proteon Therapeutics presently has a consensus price target of $3.33, suggesting a potential upside of 79.73%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 46.94%. Given Proteon Therapeutics’ higher possible upside, equities research analysts clearly believe Proteon Therapeutics is more favorable than its peers.

Summary

Proteon Therapeutics peers beat Proteon Therapeutics on 8 of the 12 factors compared.

Proteon Therapeutics Company Profile

Proteon Therapeutics, Inc. is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The Company has completed Phase II trial of vonapanitase in patients undergoing creation of an arteriovenous fistula (AVF). The Company initiated the first of two Phase III trials, PATENCY-1, for vonapanitase in radiocephalic AVFs. Its vonapanitase product candidate is a recombinant human elastase under development as a treatment to prevent AVF and arteriovenous graft (AVG) patency loss.

Receive News & Ratings for Proteon Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.